Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) will announce interim data from the ongoing Phase 1 INLIGHT trial of WVE-007 (INHBE) for obesity on Monday, December 8, 2025. A press release will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. Investors can access the live webcast via the company’s Investor Events page and an archived version will be available after the event.

This announcement covers timing and access for interim clinical data disclosure for WVE-007; no trial results or financial metrics are included in this notice.

News Market Reaction

+147.26% 56.5x vol

133 alerts

+147.26% News Effect

+132.1% Peak Tracked

-20.7% Trough Tracked

+$1.94B Valuation Impact

$3.26B Market Cap

56.5x Rel. Volume

On the day this news was published, WVE gained 147.26%, reflecting a significant positive market reaction. Argus tracked a peak move of +132.1% during that session. Argus tracked a trough of -20.7% from its starting point during tracking. Our momentum scanner triggered 133 alerts that day, indicating very high trading interest and price volatility. This price movement added approximately $1.94B to the company's valuation, bringing the market cap to $3.26B at that time. Trading volume was exceptionally heavy at 56.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Interim data date: December 8, 2025 Press release time: 7:30 a.m. ET Conference call time: 8:30 a.m. ET

3 metrics

Interim data date December 8, 2025 Phase 1 INLIGHT WVE-007 obesity trial interim data announcement

Press release time 7:30 a.m. ET Scheduled issuance of interim INLIGHT data press release

Conference call time 8:30 a.m. ET Investor conference call and webcast following interim data release

Market Reality Check

Price: $13.47 Vol: Volume 2,542,918 is modes...

normal vol

$13.47 Last Close

Volume Volume 2,542,918 is modestly above the 20-day average of 2,403,129 ahead of the interim INLIGHT data. normal

Technical Shares closed at $7.49, trading below the 200-day moving average of $7.75 and about 52% under the 52-week high of $15.72.

Peers on Argus

Peer biotech moves were mixed: ELVN +1.77%, PGEN -5.01%, STOK -0.84%, while CVAC...

Peer biotech moves were mixed: ELVN +1.77%, PGEN -5.01%, STOK -0.84%, while CVAC 0% and ZYME +0.04%. This points to stock-specific focus on WVE-007’s upcoming data rather than a broad sector move.

Historical Context

5 past events · Latest: Nov 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 10	Earnings and update	Positive	-10.3%	Q3 2025 results with WVE-007 and WVE-006 data and runway into 2Q 2027.
Nov 07	Investor conferences	Neutral	-0.3%	Management participation in November healthcare investor conferences and panels.
Nov 04	Preclinical obesity data	Positive	+0.4%	ObesityWeek® preclinical data for WVE-007 supporting fat loss with muscle preservation.
Nov 04	Earnings scheduling	Neutral	-3.6%	Announcement of timing and access details for the Q3 2025 earnings call.
Oct 29	Clinical data update	Positive	+8.8%	Corrected release on positive INLIGHT target engagement data for WVE-007 in obesity.

Pattern Detected

Clinical trial and obesity-related updates have often coincided with positive price reactions, while earnings and scheduling releases have seen weaker or negative responses.

Recent Company History

Over recent months, Wave has highlighted WVE-007’s obesity program and broader RNA pipeline. On Oct 29, 2025, positive INLIGHT target engagement data drove a +8.83% move. Preclinical obesity data on Nov 4, 2025 and conference participation had minimal impact. Q3 2025 results on Nov 10, 2025 combined strong WVE-007 and WVE-006 metrics with runway into 2Q 2027 but saw a -10.31% reaction. Today’s announcement sets expectations for the next INLIGHT data update.

Market Pulse Summary

The stock surged +147.3% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +147.3% in the session following this news. A strong positive reaction aligns with prior WVE clinical-trial updates, where news around WVE-007 and other programs often coincided with sizeable moves, such as +8.83% on INLIGHT target engagement data. However, earnings-related releases sometimes saw selling pressure. Investors monitoring such a surge would have weighed how much of the obesity data was anticipated from earlier updates and considered risks from future financings, execution on subsequent trial phases, and the potential for momentum to cool after the initial reaction.

Key Terms

phase 1, inhbe, galnac-sirna, sirna, +2 more

6 terms

phase 1 medical

"announce interim data from the ongoing Phase 1 INLIGHT clinical trial"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

inhbe medical

"INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA"

INHBE (also called activin E) is a gene that produces a small signaling protein made mainly by the liver and fat tissue that helps regulate energy use, appetite, and how the body handles sugar and fat. Investors care because drugs, diagnostics, or therapies that alter or measure INHBE activity target metabolic conditions like obesity and diabetes; mentions of INHBE in filings or releases can indicate a company is pursuing a potential treatment or biomarker that could materially affect its future value — like a thermostat companies might try to recalibrate to change how the body stores or uses energy.

galnac-sirna medical

"evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary"

GalNAc‑siRNA is a type of RNA-based drug where the therapeutic small interfering RNA (siRNA) is chemically linked to a GalNAc (a sugar) “address label” that directs the medicine specifically into liver cells after injection. For investors, this matters because the delivery method raises the chances a treatment reaches its target, often allowing lower doses, fewer side effects, and more predictable manufacturing and commercial prospects compared with RNA drugs that lack targeted delivery.

sirna medical

"evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

webcast technical

"followed by an investor conference call and webcast at 8:30 a.m. ET"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

investor relations financial

"accessed by visiting “Investor Events” on the investor relations section"

Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET.

A webcast of the conference call can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About WVE-007
WVE-007 is an investigational GalNAc-siRNA that utilizes Wave’s best-in-class proprietary oligonucleotide chemistry and the company’s Stereopure interfering Nucleic Acid (SpiNA) next generation siRNA design. WVE-007 is designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier body composition and cardiometabolic profile, including less visceral fat and lower risk of type 2 diabetes or cardiovascular disease. In preclinical models, INHBE GalNAc-siRNA led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue, supporting potential for metabolic improvement. As an add-on to semaglutide, Wave’s GalNAc-siRNA doubled weight loss in mice and prevented weight regain upon cessation of semaglutide.

About the INLIGHT Clinical Trial
INLIGHT is an ongoing, first-in-human clinical trial (3:1 active: placebo) evaluating WVE-007 in adults living with overweight or obesity and assesses safety, tolerability, pharmacokinetics, Activin E, body weight and composition, and biomarkers of metabolic health. INLIGHT is currently ongoing at multiple trial sites, including in the US.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM^®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

FAQ

When will Wave Life Sciences (WVE) announce interim INLIGHT trial data for WVE-007?

Wave will announce interim data on Monday, December 8, 2025, with a press release at 7:30 a.m. ET.

What time is the Wave Life Sciences (WVE) investor webcast for the WVE-007 INLIGHT update?

The investor conference call and webcast is scheduled for 8:30 a.m. ET on December 8, 2025.

Where can I watch the live webcast for Wave Life Sciences (WVE) interim INLIGHT data?

Watch the live webcast via the company’s Investor Events page on the Wave Life Sciences investor relations website.

Will the Wave Life Sciences (WVE) INLIGHT webcast be available after the live event?

Yes, an archived version of the webcast will be available on the Wave Life Sciences website following the live event.

What drug and indication are covered in Wave Life Sciences (WVE) December 8, 2025 announcement?

The announcement covers interim data for WVE-007 (INHBE), an investigational GalNAc-siRNA being evaluated for obesity in the Phase 1 INLIGHT trial.

Does the December 8, 2025 press release include WVE-007 trial results or financial guidance?

The notice only gives timing and access for the interim data release; it does not include trial results or financial guidance.